Switch theme
Sign up to access all valuation multiples
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
2014
17.8K+
LTM Revenue $5.5B
LTM EBITDA $1.6B
$26.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Steris has a last 12-month revenue (LTM) of $5.5B and a last 12-month EBITDA of $1.6B.
In the most recent fiscal year, Steris achieved revenue of $5.5B and an EBITDA of $1.4B.
Steris expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Steris valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| Gross Profit | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $1.6B | XXX | $1.4B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $1.3B | XXX | $961M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $936M | XXX | $615M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Steris's stock price is $245.
Steris has current market cap of $24.1B, and EV of $26.2B.
See Steris trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.2B | $24.1B | XXX | XXX | XXX | XXX | $9.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Steris has market cap of $24.1B and EV of $26.2B.
Steris's trades at 4.9x EV/Revenue multiple, and 19.1x EV/EBITDA.
Equity research analysts estimate Steris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Steris has a P/E ratio of 25.8x.
See valuation multiples for Steris and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24.1B | XXX | $24.1B | XXX | XXX | XXX |
| EV (current) | $26.2B | XXX | $26.2B | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 19.1x | XXX | XXX | XXX |
| EV/EBIT | 20.4x | XXX | 27.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.8x | XXX | 43.4x | XXX | XXX | XXX |
| EV/FCF | 33.5x | XXX | 35.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSteris's last 12 month revenue growth is 6%
Steris's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Steris's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Steris's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Steris and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Steris acquired XXX companies to date.
Last acquisition by Steris was XXXXXXXX, XXXXX XXXXX XXXXXX . Steris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Steris founded? | Steris was founded in 2014. |
| Where is Steris headquartered? | Steris is headquartered in United States of America. |
| How many employees does Steris have? | As of today, Steris has 17.8K+ employees. |
| Who is the CEO of Steris? | Steris's CEO is Mr. Daniel A. Carestio. |
| Is Steris publicy listed? | Yes, Steris is a public company listed on NYS. |
| What is the stock symbol of Steris? | Steris trades under STE ticker. |
| When did Steris go public? | Steris went public in 1992. |
| Who are competitors of Steris? | Similar companies to Steris include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Steris? | Steris's current market cap is $24.1B |
| What is the current revenue of Steris? | Steris's last 12 months revenue is $5.5B. |
| What is the current revenue growth of Steris? | Steris revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Steris? | Current revenue multiple of Steris is 4.7x. |
| Is Steris profitable? | Yes, Steris is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Steris? | Steris's last 12 months EBITDA is $1.6B. |
| What is Steris's EBITDA margin? | Steris's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Steris? | Current EBITDA multiple of Steris is 16.3x. |
| What is the current FCF of Steris? | Steris's last 12 months FCF is $780M. |
| What is Steris's FCF margin? | Steris's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Steris? | Current FCF multiple of Steris is 33.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
